Please use this identifier to cite or link to this item:
http://repositorio.isalud.edu.ar/xmlui/handle/123456789/2044
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Urueña, Analía | - |
dc.contributor.author | Micone, Paula | - |
dc.contributor.author | Magneres, María Cecilia | - |
dc.contributor.author | McGovern, Ian | - |
dc.contributor.author | Mould-Quevedo, Joaquín | - |
dc.contributor.author | Rocha Sarmento, Túlio Tadeu | - |
dc.contributor.author | Giglio, Norberto | - |
dc.date.accessioned | 2024-10-30T20:29:13Z | - |
dc.date.available | 2024-10-30T20:29:13Z | - |
dc.date.issued | 2022 | - |
dc.identifier.citation | Urueña A, Micone P, Magneres MC, McGovern I, Mould-Quevedo J, Sarmento TTR, Giglio N. Cost-Effectiveness Analysis of Cell Versus Egg-Based Seasonal Influenza Vaccination in Children and Adults in Argentina. Vaccines. 2022; 10(10):1627. https://doi.org/10.3390/vaccines10101627 | es_AR |
dc.identifier.uri | https://doi.org/10.3390/vaccines10101627 | - |
dc.identifier.uri | http://repositorio.isalud.edu.ar/xmlui/handle/123456789/2044 | - |
dc.identifier.uri | https://www.mdpi.com/2076-393X/10/10/1627 | |
dc.description.abstract | Background: Quadrivalent cell-based influenza vaccines (QIVc) avoid egg-adaptive mutations and can be more effective than traditional quadrivalent egg-based influenza vaccines (QIVe). This analysis compared the cost-effectiveness of QIVc and QIVe in Argentinian populations < 65 years old from the payer and societal perspectives. Methods: A static decision tree model compared the costs and health benefits of vaccination with QIVc vs. QIVe using a one-year time horizon. The relative vaccine effectiveness of QIVc vs. QIVe was assumed to be 8.1% for children and 11.4% for adults. An alternative high egg-adaptation scenario was also assessed. Model inputs were sourced from Argentina or the international literature. Deterministic and probabilistic sensitivity analyses were performed. Results: Compared to QIVe, QIVc would prevent 17,857 general practitioner visits, 2418 complications, 816 hospitalizations, and 12 deaths per year. From the payers’ perspective, the incremental cost-effectiveness ratio per quality-adjusted life years gained was USD12,214 in the base case and USD2311 in the high egg-adaptation scenario. QIVc was cost-saving from the societal perspective in both scenarios. Conclusions: QIVc in Argentina would be cost-effective relative to QIVe. The potential health benefits and savings would be even higher in high egg-adaptation seasons. | es_AR |
dc.language.iso | en | es_AR |
dc.subject | Influenza | es_AR |
dc.subject | Vacunas | es_AR |
dc.subject | Costo efectividad | es_AR |
dc.subject | Vacuna basada en células | es_AR |
dc.title | Cost-Effectiveness Analysis of Cell Versus Egg-Based Seasonal Influenza Vaccination in Children and Adults in Argentina | es_AR |
dc.type | Article | es_AR |
dc.description.fil | Fil: Urueña A. Centro de Estudios para la Prevención y Control de Enfermedades Transmisibles, Universidad Isalud, Venezuela 931, Ciudad Autónoma de Buenos Aires C1095AAS, Argentina | es_AR |
Appears in Collections: | Trabajos Publicados |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Urueña. Vaccines-10(10).pdf | 2,21 MB | Adobe PDF | ![]() View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.